We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Alector Inc | NASDAQ:ALEC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.21 | 3.30% | 6.58 | 6.38 | 6.85 | 6.78 | 6.38 | 6.42 | 778,149 | 23:00:01 |
Poster presentations will be available for on-demand viewing beginning on July 28 at 8:00 a.m. ET.
AL002 Presentations TREM2 Program (AL002) is Being Developed in Collaboration with AbbVie
Poster Title: Baseline characteristics for INVOKE-2: a phase 2 randomized, double-blind, placebo-controlled study evaluating AL002 in early Alzheimer’s disease (#95594)Presenting Author: Arthur J. Mayorga, Ph.D., Vice President, Clinical Development Neurology, Alector Session Date and Time: Sunday, July 28, 2024 from 8:00 a.m. – 4:15 p.m. ET
Poster Title: Use of a blood-based amyloid test for screening in INVOKE-2: a phase 2 randomized, double-blind, placebo-controlled study evaluating AL002 in early Alzheimer’s disease (#95646)Presenting Author: Brady Burgess, Ph.D., Staff Scientist, Alector Session Date and Time: Monday, July 29, 2024 from 8:00 a.m. – 4:15 p.m. ET
Progranulin PresentationsProgranulin Programs (latozinemab (AL001) and AL101/GSK4527226) are Being Developed in Collaboration with GSK
Poster Title: Using plasma biomarkers to distinguish TDP43 associated pathologies (#89291)Presenting Author: Gopi Ganji, Ph.D., Scientific Leader, GSKSession Date and Time: Monday, July 29, 2024 from 8:00 a.m. – 4:15 p.m. ET
Poster Title: PROGRESS-AD: a phase 2 study to evaluate efficacy and safety of GSK4527226 (AL101), an anti-sortilin monoclonal antibody, in patients with early Alzheimer's disease (#90247)Presenting Author: Christine Bailey, Ph.D., Clinical Development Director, GSK Session Date and Time: Sunday, July 28, 2024 from 8:00 a.m. – 4:15 p.m. ET
Poster Topic: Genetics, progranulin, and Alzheimer’s disease (#89497)Presenting Author: Chun-Fand Xu, Ph.D., Senior Director, Human Genetics Senior Director, GSKSession Date and Time: Sunday, July 28, 2024 from 8:00 a.m. – 4:15 p.m. ET
About AlectorAlector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
Alector Contacts:
AlectorKatie Hogan202-549-0557katie.hogan@alector.com
1AB (media)Dan Budwick973-271-6085 dan@1abmedia.com
Argot Partners (investors)Laura Perry212.600.1902alector@argotpartners.com
1 Year Alector Chart |
1 Month Alector Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions